CD24 and triple-negative breast carcinoma: Short-term Olaparib treatment has also been previously demonstrated to induce cancer cell invasion and enrich PD-L1 and CD44+CD24– stemness marker levels in triple-negative breast cancer (TNBC) cell lines (43).